Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Advanced age is a consistent risk factor for the incidence of postoperative cognitive decline, which is associated with longer hospital stays, decreased quality of life, and increased mortality. Anaesthetic drugs can also affect postoperative cognition, as their residual effects can alter central nervous system activity. Desflurane and sevoflurane are widely used volatile anesthetics. Choice anesthetics may influence the occurrence of postoperative delirium. However, evidence in this aspect is conflicting.
With increasing life expectancy, more and more patients aged 65 or older will receive general anesthesia. Rapid recovery from anesthesia may reduce the incidence of many postoperative complications, such as postoperative delirium and cognitive dysfunction. Using inhalational anesthetics is the mainstay of general anesthesia. Since they pass readily into the brain, anesthetics are usually recognized as the important cause of postoperative cognitive dysfunction. Studies have shown that inhalation anesthesia may increase the risk of postoperative delirium in elderly patients compared to propofol, but such studies mostly focus on isoflurane and sevoflurane. Concentrations isoflurane caused aggregation of amyloid peptides in cell cultures, indicating that they brought cytotoxicity to the brain; sevoflurane also showed the same cytotoxic effect. However, some studies showed that inhalational anesthetics had a protective effect on postoperative cognitive function. Desflurane is currently known to be the least biotransformation inhaled anesthetic, whose blood-gas partition coefficient is only 0.42. Desflurane is increasingly used in elderly patients in clinical practice. However, it is not clear whether general anesthesia maintained mainly by desflurane reduces postoperative delirium and early cognitive dysfunction compared with sevoflurane-based general anesthesia
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sevoflurane group | Active Comparator | Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Sevoflurane inhalation will be stopped at the end of surgery. |
|
| Desflurane group | Experimental | Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Desflurane inhalation will be stopped at the end of surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Desflurane | Drug | Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| postoperative delirium | Delirium is assessed twice daily with the Confusion Assessment Method for patients without endotracheal intubation or the Confusion Assessment Method for the Intensive Care Unit for patients with endotracheal intubation. | within 7 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of recovery, QoR15 (Quality of Recovery 15) | Quality of recovery-15 questionnaire, which consists 15 questions. The score ranges from 0 to 150. The higher the score, the better the quality of recovery. | The day before surgery and on the 7th day after surgery or discharge |
| Subjective sleep quality (NRS) within 3 days after surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive function at 30 days after surgery | Cognitive function assessed with Telephone Interview for Cognitive Status-Modified (TICS-m) | On the 30th day after surgery |
| TNF-α concentration | Blood specimens will be taken for measuring TNF-α, which is measured with liquid chromatography-mass spectrometry. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jing Yang, MD,PhD | Contact | +86- 18980602269 | yangjing@wchscu.cn | |
| Min Xu | Contact | +86-13281155917 | 18706782887@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jing Yang, MD,PhD | West China Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology, West China Hospital | Recruiting | Chengdu | Sichuan | 610041 | China |
Not provided
| ID | Term |
|---|---|
| D003693 | Delirium |
| D000079690 | Postoperative Cognitive Complications |
| ID | Term |
|---|---|
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077335 | Desflurane |
| D000077149 | Sevoflurane |
| ID | Term |
|---|---|
| D005019 | Ethyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D008738 | Methyl Ethers |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Sevoflurane | Drug | Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery. |
|
Subjective sleep quality is assessed once daily with the Numeric Rating Scale (an 11-point rating scale where 0 = the worst sleep and 10 = the best sleep). |
| Up to 3 days after surgery |
| Length of stay in hospital after surgery. | Length of stay in hospital after surgery | Up to 30 days after surgery |
| Percentage of intensive care unit (ICU) admission after surgery. | Percentage of intensive care unit (ICU) admission after surgery | Within 24 hours after surgery |
| Length of stay in ICU after surgery. | Length of stay in ICU after surgery (in patients admitted to the ICU after surgery) | Up to 30 days after surgery |
| Incidence of complications within 30 days | Complications are defined as newly occurred events that are harmful to patients' recovery and required therapeutic intervention | Up to 30 days after surgery |
| Intensity of pain within 3 days after surgery | Intensity of pain is assessed twice daily (8-10 AM and 6-8 PM) with the Numeric Rating Scale (an 11-point rating scale where 0 = no pain and 10 = the worst pain). | Up to 3 days after surgery |
| Incidence of postoperative cognitive dysfunction (POCD) | Postoperative changes in Neuropsychological Tests score compared with baseline preoperative Neuropsychological Test scores in both the groups. | The day before surgery and on the 7th day after surgery or discharge |
| The day before surgery and 24 hours after surgery. Performed in part of enrolled patients. |
| IL-6 concentration | Blood specimens will be taken for measuring IL-6, which is measured with fluorescence immunochromatography | The day before surgery and 24 hours after surgery. Performed in part of enrolled patients. |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D060825 | Cognitive Dysfunction |
| D003072 | Cognition Disorders |
| D006845 |
| Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |